Three monthly doses of palivizumab are not adequate for 5-month protection: Apopulation pharmacokinetic analysis

Pulmonary Pharmacology and Therapeutics

Volumn 26, Issue 6, 2013, Pages 666-671

  La Via, William V ^a   Notario, Gerard F ^b   Yu, Xiang Qing ^a   Sharma, Shringi ^b   Noertersheuser, Peter A ^b   Robbie, Gabriel J ^a  

^a MEDIMMUNE   (United States)

^b ABBOTT LABORATORIES   (United States)

Author keywords

Bronchopulmonary dysplasia (BPD); Chronic lung disease (CLD); Monoclonal antibody; Pediatric; Premature infant; Respiratory syncytial virus (RSV)

Indexed keywords

PALIVIZUMAB;

ARTICLE; CHRONIC LUNG DISEASE; COMPARTMENT MODEL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG EXPOSURE; DRUG HALF LIFE; GESTATIONAL AGE; HUMAN; INFANT; MAJOR CLINICAL STUDY; PREMATURITY; PRIORITY JOURNAL; RESPIRATORY SYNCYTIAL VIRUS INFECTION;

BRONCHOPULMONARY DYSPLASIA (BPD); CHRONIC LUNG DISEASE (CLD); MONOCLONAL ANTIBODY; PEDIATRIC; PREMATURE INFANT; RESPIRATORY SYNCYTIAL VIRUS (RSV);

AGE FACTORS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIVIRAL AGENTS; BRITISH COLUMBIA; CLINICAL TRIALS AS TOPIC; DRUG ADMINISTRATION SCHEDULE; HUMANS; INFANT; INJECTIONS, INTRAMUSCULAR; MODELS, BIOLOGICAL; PRACTICE GUIDELINES AS TOPIC; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RISK FACTORS; TIME FACTORS;

EID: 84887990669     PISSN: 10945539     EISSN: 15229629     Source Type: Journal    
DOI: 10.1016/j.pupt.2013.03.007     Document Type: Article

References (34)

1. Hall C.B. Nosocomial respiratory syncytial virus infections: the "Cold War" has not ended. Clin Infect Dis 2000, 31(2):590-596.
2. Simoes E.A. Respiratory syncytial virus infection. Lancet 1999, 354(9181):847-852.
3. Zhang W., Tripp R.A. RNA interference inhibits respiratory syncytial virus replication and disease pathogenesis without inhibiting priming of the memory immune response. JVirol 2008, 82(24):12221-12231.
4. Hall C.B., Walsh E.E. Respiratory syncytial virus. Textbook of pediatric infectious diseases 2009, 2462-2487. WB Saunders, Philadelphia, PA. 6th ed.
5. Stockman L.J., Curns A.T., Anderson L.J., Fischer-Langley G. Respiratory syncytial virus-associated hospitalizations among infants and young children in the United States, 1997-2006. Pediatr Infect Dis J 2012, 31(1):5-9.
6. Boyce T.G., Mellen B.G., Mitchel E.F., Wright P.F., Griffin M.R. Rates of hospitalization for respiratory syncytial virus infection among children in Medicaid. JPediatr 2000, 137(6):865-870.
7. Johnson S., Oliver C., Prince G.A., Hemming V.G., Pfarr D.S., Wang S.C., et al. Development of a humanized monoclonal antibody (MEDI-493) with potent invitro and invivo activity against respiratory syncytial virus. JInfect Dis 1997, 176(5):1215-1224.
8. Synagis® (palivizumab) Full prescribing information 2012, MedImmune, LLC, Gaithersburg, MD.
9. Mutuc J.D., Langley G.E. Respiratory syncytial virus-United States, July 2007-June 2011. MMWR Morb Mortal Wkly Rep 2011, 60(35):1203-1206.
10. Panozzo C.A., Stockman L.J., Curns A.T., Anderson L.J. Use of respiratory syncytial virus surveillance data to optimize the timing of immunoprophylaxis. Pediatrics 2010, 126(1):e116-e123.
11. Checon R.E., Siqueira M.M., Lugon A.K., Portes S., Dietze R. Short report: seasonal pattern of respiratory syncytial virus in a region with a tropical climate in southeastern Brazil. Am J Trop Med Hyg 2002, 67(5):490-491.
12. De Silva L.M., Hanlon M.G. Respiratory syncytial virus: a report of a 5-year study at a children's hospital. JMed Virol 1986, 19(4):299-305.
13. Forshey B.M., Laguna-Torres V.A., Vilcarromero S., Bazan I., Rocha C., Morrison A.C., et al. Epidemiology of influenza-like illness in the Amazon Basin of Peru, 2008-2009. Influenza Other Respi Virus 2010, 4(4):235-243.
14. Goddard N.L., Cooke M.C., Gupta R.K., Nguyen-Van-Tam J.S. Timing of monoclonal antibody for seasonal RSV prophylaxis in the United Kingdom. Epidemiol Infect 2007, 135(1):159-162.
15. Mlinaric-Galinovic G., Vojnovic G., Cepin-Bogovic J., Bace A., Bozikov J., Welliver R.C., et al. Does the viral subtype influence the biennial cycle of respiratory syncytial virus?. Virol J 2009, 6:133.
16. Straliotto S.M., Nestor S.M., Siqueira M.M. Respiratory syncytial virus groups A and B in Porto Alegre, Brazil, from 1990 to 1995 and 1998. Mem Inst Oswaldo Cruz 2001, 96(2):155-158.
17. World Health Organization. Acute respiratory infections. Available from:. [accessed 05.02.13]. http://www.who.int/vaccine_research/diseases/ari/en/index.html.
18. Yusuf S., Piedimonte G., Auais A., Demmler G., Krishnan S., Van Caeseele P., et al. The relationship of meteorological conditions to the epidemic activity of respiratory syncytial virus. Epidemiol Infect 2007, 135(7):1077-1090.
19. Moura F.E., Nunes I.F., Silva G.B., Siqueira M.M. Respiratory syncytial virus infections in northeastern Brazil: seasonal trends and general aspects. Am J Trop Med Hyg 2006, 74(1):165-167.
20. Robertson S.E., Roca A., Alonso P., Simoes E.A., Kartasasmita C.B., Olaleye D.O., et al. Respiratory syncytial virus infection: denominator-based studies in Indonesia, Mozambique, Nigeria and South Africa. Bull World Health Organ 2004, 82(12):914-922.
21. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics 1998, 102(3 Pt 1):531-537. The IMpact-RSV Study Group.
22. Subramanian K.N., Weisman L.E., Rhodes T., Ariagno R., Sanchez P.J., Steichen J., et al. Safety, tolerance and pharmacokinetics of a humanized monoclonal antibody to respiratory syncytial virus in premature infants and infants with bronchopulmonary dysplasia. MEDI-493 Study Group. Pediatr Infect Dis J 1998, 17(2):110-115.
23. Frogel M., Nerwen C., Cohen A., VanVeldhuisen P., Harrington M., Boron M. Prevention of hospitalization due to respiratory syncytial virus: results from the Palivizumab Outcomes Registry. JPerinatol 2008, 28(7):511-517.
24. Oh P.I., Lanctjt K.L., Yoon A., Lee D.S., Paes B.A., Simmons B.S., et al. Palivizumab prophylaxis for respiratory syncytial virus in Canada: utilization and outcomes. Pediatr Infect Dis J 2002, 21(6):512-518.
25. Simon A., Nowak H., Sterz R. Use of palivizumab in Germany: data from 2002-2007. Klin Padiatr 2011, 223(5):292-298.
26. Solimano A, Kwan E. Revisiting palivizumab (PVZ) dosing recommendations based on published pharmacokinetics data. In: Presented at: Pediatric Academic Societies; April 28-May 1, 2012; Boston, MA.
27. Weiner L.B., Masaquel A.S., Polak M.J., Mahadevia P.J. Cost-effectiveness analysis of palivizumab among pre-term infant populations covered by Medicaid in the United States. JMed Econ 2012, 15(5):997-1018.
28. Mahadevia P.J., Masaquel A.S., Polak M.J., Weiner L.B. Cost utility of palivizumab prophylaxis among pre-term infants in the United States: a national policy perspective. JMed Econ 2012, 15(5):987-996.
29. Chirico G., Ravasio R., Sbarigia U. Cost-utility analysis of palivizumab in Italy: results from a simulation model in the prophylaxis of respiratory syncytial virus infection (RSV) among high-risk preterm infants. Ital J Pediatr 2009, 35(1):4.
30. Nuijten M.J., Wittenberg W., Lebmeier M. Cost effectiveness of palivizumab for respiratory syncytial virus prophylaxis in high-risk children: a UK analysis. Pharmacoeconomics 2007, 25(1):55-71.
31. Resch B., Gusenleitner W., Nuijten M.J., Lebmeier M., Wittenberg W. Cost-effectiveness of palivizumab against respiratory syncytial viral infection in high-risk children in Austria. Clin Ther 2008, 30(4):749-760.
32. Robbie G.J., Zhao L., Mondick J., Losonsky G., Roskos L.K. Population pharmacokinetics of palivizumab, a humanized anti-respiratory syncytial virus monoclonal antibody, in adults and children. Antimicrob Agents Chemother 2012, 56(9):4927-4936.
33. Feltes T.F., Cabalka A.K., Meissner H.C., Piazza F.M., Carlin D.A., Top F.H., et al. Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease. JPediatr 2003, 143(4):532-540.
34. Johnson S., Griego S.D., Pfarr D.S., Doyle M.L., Woods R., Carlin D., et al. Adirect comparison of the activities of two humanized respiratory syncytial virus monoclonal antibodies: MEDI-493 and RSHZl9. JInfect Dis 1999, 180(1):35-40.